Search results for "Cutaneou"

showing 10 items of 1022 documents

Lipoic acid lessens Th1-mediated inflammation in lipopolysaccharide-induced uveitis reducing selectively Th1 lymphocytes-related cytokines release

2013

AbstractInflammation results in the production of free radicals. We evaluated the anti-inflammatory and antioxidant capacity of lipoic acid in an experimental uveitis model upon a subcutaneous injection of endotoxin into Lewis rats. The role of oxidative stress in the endotoxin-induced uveitis model is well-known. Besides, the Th1 response classically performs a central part in the immunopathological process of experimental autoimmune uveitis. Exogenous sources of lipoic acid have been shown to exhibit antioxidant and anti-inflammatory properties. Our results show that lipoic acid treatment plays a preventive role in endotoxin-induced oxidative stress at 24 h post-administration and reduced…

LipopolysaccharidesMaleAntioxidantantioxidantLipopolysaccharidemedicine.medical_treatmentInflammationPharmacologymedicine.disease_causeBiochemistryAntioxidantsUveitischemistry.chemical_compoundSubcutaneous injectionmedicineAnimalsInflammationTh1 lymphocytesTh2 lymphocytesThioctic AcidChemistryAnti-Inflammatory Agents Non-SteroidalGeneral MedicineTh1 Cellsmedicine.diseaselipoic acidcytokinesRatsCellular infiltrationLipoic acidDisease Models AnimalRats Inbred LewImmunologyuveitisCytokineslipids (amino acids peptides and proteins)medicine.symptomOxidative stressUveitis
researchProduct

Treatment of small hepatocellular carcinoma associated with cirrhosis by percutaneous ethanol injection. A trial with a comparison group.

1997

Ethanol injection has been reported to be effective in the treatment of hepatocellular carcinoma, but no controlled randomized trials have been performed. We therefore performed a trial comparing ethanol injection with an untreated, matched historical comparison group in the treatment of hepatocellular carcinoma.From 1992 to 1993, 35 patients (14 Child's A and 21 Child's B cirrhosis) with small (4 cm) hepatocellular carcinoma associated with cirrhosis were treated by ethanol injection. Each patient was matched with an untreated case (followed up during the period 1984-89) for variables known to have independent prognostic value (age, Child's classification, number of lesions, alpha-fetoprot…

Liver CirrhosisMalemedicine.medical_specialtyCirrhosisCarcinoma Hepatocellularmedicine.medical_treatmentEthanol InjectionGastroenterologylaw.inventionRandomized controlled triallawInternal medicinemedicineHumansChemotherapyEthanolbusiness.industryLiver NeoplasmsGastroenterologyMiddle Agedmedicine.diseaseConfidence intervalSurvival RateHepatocellular carcinomaCase-Control StudiesSolventsFemalePercutaneous ethanol injectionComplicationbusinessScandinavian journal of gastroenterology
researchProduct

Treatment of small hepatocellular carcinoma with percutaneous ethanol injection: a validated prognostic model.

2000

OBJECTIVE: Percutaneous ethanol injection may prolong the survival of patients with small hepatocellular carcinoma associated with cirrhosis. The aim was to identify prognostic factors of survival and of local recurrence, as well as separate new lesions. METHODS: We performed Cox regression analysis in 115 consecutive patients with hepatocellular carcinoma (81 Child-Pugh class A, 34 Child-Pugh class B) treated by percutaneous ethanol injection. The validity of the model was tested by comparing predicted and observed survival in 105 independent patients from an external series. RESULTS: Overall survival rates were 89%, 63%, and 43% at 1, 2, and 3 yr, respectively. The 1-, 2-, and 3-yr surviv…

Liver CirrhosisMalemedicine.medical_specialtyCirrhosisCarcinoma Hepatocellularmedicine.medical_treatmentInjections IntralesionalSmall-cell carcinomaGastroenterologyLiver Function TestsInternal medicinemedicineCarcinomaHumansSurvival rateSerum AlbuminAgedHepatologymedicine.diagnostic_testEthanolbusiness.industryProportional hazards modelLiver NeoplasmsGastroenterologyMiddle Agedmedicine.diseasedigestive system diseasesSurgerySurvival RateHepatocellular carcinomaFemalePercutaneous ethanol injectionbusinessLiver function testsFollow-Up StudiesThe American journal of gastroenterology
researchProduct

Radiofrequency thermal ablation vs. percutaneous ethanol injection for small hepatocellular carcinoma in cirrhosis: meta-analysis of randomized contr…

2009

Radiofrequency thermal ablation (RF) and percutaneous ethanol injection (PEI) have been employed in the treatment of small hepatocellular carcinoma (HCC) as curative treatments. The aim of the study was to review the available evidence comparing RF to PEI for small HCC.Cochrane, MEDLINE, CANCERLIT, and ENBASE databases were used.randomized clinical trials evaluating RF vs. PEI. Data were extracted from each randomized controlled trial (RCT). Primary outcomes were overall survival and local recurrence. Meta-analysis software was used and risk differences (RDs) and their 95% confidence intervals and Q-test for heterogeneity were calculated.Five RCTs were identified including 701 patients. The…

Liver Cirrhosismedicine.medical_specialtyCirrhosisCarcinoma Hepatocellularmedicine.medical_treatmentThermal ablationUrologyCatheter ablationInjections Intralesionallaw.inventionRandomized controlled triallawmedicineHumansSurvival rateRandomized Controlled Trials as TopicHepatologyEthanolbusiness.industryLiver NeoplasmsGastroenterologymedicine.diseaseSurgerySurvival RateTreatment OutcomeMeta-analysisHepatocellular carcinomaCatheter AblationSolventsPercutaneous ethanol injectionbusinessThe American journal of gastroenterology
researchProduct

Fibroblast Growth Factor 21 Limits Lipotoxicity by Promoting Hepatic Fatty Acid Activation in Mice on Methionine and Choline-Deficient Diets

2014

Background & Aims Nonalcoholic fatty liver disease is a common consequence of human and rodent obesity. Disruptions in lipid metabolism lead to accumulation of triglycerides and fatty acids, which can promote inflammation and fibrosis and lead to nonalcoholic steatohepatitis. Circulating levels of fibroblast growth factor (FGF)21 increase in patients with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis; therefore, we assessed the role of FGF21 in the progression of murine fatty liver disease, independent of obesity, caused by methionine and choline deficiency. Methods C57BL/6 wild-type and FGF21-knockout (FGF21-KO) mice were placed on methionine- and choline-deficient (MCD)…

Liver Cirrhosismedicine.medical_specialtyTime FactorsBiologyInfusions SubcutaneousSeverity of Illness IndexArticleHepatitischemistry.chemical_compoundAcyl-CoAMethionineNon-alcoholic Fatty Liver DiseaseInternal medicineNonalcoholic fatty liver diseasemedicineAnimalsRNA MessengerMice Knockoutchemistry.chemical_classificationHepatologyFatty acid metabolismFatty AcidsFatty liverGastroenterologyFatty acidmedicine.diseaseRecombinant ProteinsCholine DeficiencyFibroblast Growth FactorsMice Inbred C57BLDisease Models AnimalEndocrinologyLiverchemistryLipotoxicityDisease ProgressionLipid PeroxidationInflammation MediatorsSteatosisLong chain fatty acidOxidation-ReductionGastroenterology
researchProduct

THE USE OF INTERLEUKIN 1 RECEPTOR ANTAGONIST (ANAKINRA) IN KAWASAKI DISEASE: A RETROSPECTIVE CASES SERIES

2018

Introduction: Persistent fever and inflammation after infusion of 2g/kg of IVIG, the standard treatment of KD represents a high-risk situation for coronary aneurysms in Kawasaki disease. Identifying patients at risk for IVIG resistance is difficult outside the Asian population, and there remains a critical unmet need to identify an anti-inflammatory treatment that is efficacious in all KD patients. Recent evidence from studies in animals and humans suggest a critical role for interleukin-1 (IL-1) α and β in the pathogenesis of KD. Objectives: To identify the clinical characteristics, reasons for use and response to treatment with anakinra in a retrospective series of patients with Kawasaki …

Male0301 basic medicineBLOCKADEPlacebo-controlled studyCHILDRENSUSCEPTIBILITYPLACEBO-CONTROLLED TRIALPediatricsDOUBLE-BLIND0302 clinical medicineSettore MED/38 - Pediatria Generale E SpecialisticaRetrospective StudieINTERLEUKIN 1 RECEPTOR ANTAGONIST ANAKINRA KAWASAKI DISEASEImmunology and AllergyJUVENILE IDIOPATHIC ARTHRITISChildPediatricAnakinra coronary artery aneurysmPrognosis1107 ImmunologyChild PreschoolDisease ProgressionFemaleVasculitisLife Sciences & BiomedicineHumanmedicine.drugVasculitismusculoskeletal diseasesAutoinflammatory diseaseVasculitimedicine.medical_specialtyMyocarditisPrognosiImmunologyMucocutaneous Lymph Node SyndromeAnakinra coronary artery aneurysms03 medical and health sciencesInternal medicineINFLIXIMABMANAGEMENTmedicineINTRAVENOUS IMMUNOGLOBULINHumansRetrospective Studies030203 arthritis & rheumatologyAnakinraScience & TechnologyKawasaki diseasebusiness.industryInfantReceptors Interleukin-1Retrospective cohort studymedicine.diseaseInfliximabInterleukin 1 Receptor Antagonist Protein030104 developmental biologyInterleukin 1 receptor antagonistKawasaki diseasebusinessInterleukin-1
researchProduct

Absence of germline CDKN2A mutation in Sicilian Patients with Familial Malignant Melanoma: could it be a population-specific genetic signature?

2015

Germline CDKN2A mutations have been described in 25% to 40% of melanoma families from several countries. Sicilian population is genetically different from the people of Europe and Northern Italy because of its historical background, therefore familial melanoma could be due to genes different from high-penetrance CDKN2A gene. Four hundred patients with cutaneous melanoma were observed in a 6-years period at the Plastic Surgery Unit of the University of Palermo. Forty-eight patients have met the criteria of the Italian Society of Human Genetics (SIGU) for the diagnosis of familial melanoma and were screened for CDKN2A and CDK4 mutations. Mutation testing revealed that none of the families car…

Male0301 basic medicineCancer ResearchMutation rateSettore MED/06 - Oncologia MedicaSettore MED/19 - Chirurgia Plasticap14ARFGermline0302 clinical medicineCDKN2ATumor Suppressor Protein p14ARFMedicineMelanomaSicilyfamilial melanomaGeneticseducation.field_of_studyMelanomaMiddle AgedGene Expression Regulation NeoplasticItalyOncologygermline mutation030220 oncology & carcinogenesisMolecular MedicineFemaleResearch PaperSignal TransductionAdultPopulation03 medical and health sciencesCDKN2Acutaneous melanomaGermline mutationp16INK4aHumansGenetic Predisposition to DiseaseeducationneoplasmsCyclin-Dependent Kinase Inhibitor p16Germ-Line MutationAgedPharmacologybusiness.industryGenetic heterogeneityp.R87W mutationmedicine.disease030104 developmental biologyMutationCutaneous melanomaCDKN2A; cutaneous melanoma; familial melanoma; germline mutation; p.R87W mutation; p14ARF; p16INK4a; Cancer Research; Oncology; Molecular Medicine; Pharmacologybusiness
researchProduct

Efficacy of N-acetylcysteine in the prevention of alcohol relapse-like drinking: Study in long-term ethanol-experienced male rats

2021

Alcohol use disorders are chronic and highly relapsing disorders, thus alcoholic patients have a high rate of recidivism for drug use even after long periods of abstinence. The literature points to the potential usefulness of N-acetylcysteine (NAC) in the management of several substance use disorders probably due to its capacity to restore brain homeostasis of the glutamate system disrupted in addiction. However, there is little evidence in the case of alcohol. The aim of this study was to explore the potential anti-relapse efficacy of NAC using the alcohol deprivation effect (ADE) model in long-term experienced rats. Two experiments were performed in male Wistar rats to: (a) test the effic…

Male0301 basic medicineDrugAlcohol DrinkingInjections Subcutaneousmedia_common.quotation_subjectDrug Evaluation PreclinicalAlcoholPharmacologyInfusions Subcutaneous:CIENCIAS DE LA VIDA [UNESCO]ethanol relapse preventionAcetylcysteineRandom Allocation03 medical and health sciencesCellular and Molecular Neurosciencechemistry.chemical_compoundSubcutaneous injection0302 clinical medicinePharmacotherapyalcohol use disordersRecurrenceglutamate neurotransmissionUNESCO::CIENCIAS DE LA VIDAAnimalsMedicineRats Wistarmedia_commonEthanolEthanolbusiness.industryAbstinencealcohol deprivation effecAcetylcysteineRatsSubstance Withdrawal SyndromeAlcoholismRegimen030104 developmental biologychemistryModels Animalbusiness030217 neurology & neurosurgerymedicine.drug
researchProduct

Kawasaki disease triggered by EBV virus in a child with Familial Mediterranean Fever

2019

Abstract Background Familial Mediterranean Fever is a monogenic autoinflammatory disease, secondary to mutation of MEFV gene, and typically expressed with recurrent attacks of fever, serositis, rash, aphthous changes in lips and/or oral mucosa. Kawasaki Disease, an acute systemic vasculitis with persistent fever (5 or more days), rash, stomatitis, conjunctivitis, lymphadenopathy, changes in extremities, is currently considered a multifactorial autoinflammatory disease. An infection, as Epstein Barr virus, can be the trigger of Kawasaki Disease. Case presentation We describe the clinical case of a 3-year-old boy with Kawasaki disease. Successfully treated with intravenous immune globulin, ac…

Male0301 basic medicineEpstein-Barr Virus InfectionsFamilial Mediterranean feverCase ReportMucocutaneous Lymph Node SyndromeFamilial Mediterranean fever03 medical and health sciencesSettore MED/38 - Pediatria Generale E Specialistica0302 clinical medicinehemic and lymphatic diseasesmedicineHumansskin and connective tissue diseasesEpstein–Barr virus infectionKawasaki diseasebusiness.industrylcsh:RJ1-570Epstein Barr viruslcsh:Pediatricsmedicine.diseaseMEFVRashPharyngitis030104 developmental biologyChild PreschoolEpstein Barr viruImmunologyKawasaki diseasemedicine.symptombusinessSerositis030217 neurology & neurosurgerySystemic vasculitisItalian Journal of Pediatrics
researchProduct

Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes.

2018

BACKGROUND: Familial Mediterranean fever, mevalonate kinase deficiency (also known as the hyperimmunoglobulinemia D syndrome), and the tumor necrosis factor receptor-associated periodic syndrome (TRAPS) are monogenic autoinflammatory diseases characterized by recurrent fever flares. METHODS: We randomly assigned patients with genetically confirmed colchicine-resistant familial Mediterranean fever, mevalonate kinase deficiency, or TRAPS at the time of a flare to receive 150 mg of canakinumab subcutaneously or placebo every 4 weeks. Patients who did not have a resolution of their flare received an add-on injection of 150 mg of canakinumab. The primary outcome was complete response (resolution…

Male0301 basic medicineInterleukin-1betaFamilial Mediterranean fever0302 clinical medicineMonoclonalChildMedicine(all)Mevalonate kinase deficiencySubcutaneousMedicine (all)Interleukin-1betaAntibodies MonoclonalGeneral MedicineFamilial Mediterranean FeverRecurrent feverChild PreschoolFemaleTumor necrosis factor alphaDrugInflammatory diseases Radboud Institute for Molecular Life Sciences [Radboudumc 5]medicine.drugAdultAdolescentFeverInjections SubcutaneousHereditary Autoinflammatory DiseasesAntibodies Monoclonal HumanizedAdolescent; Adult; Antibodies Monoclonal/administration & dosage; Antibodies Monoclonal/adverse effects; Antibodies Monoclonal/therapeutic use; Child; Child Preschool; Dose-Response Relationship Drug; Double-Blind Method; Familial Mediterranean Fever/drug therapy; Female; Fever/drug therapy; Hereditary Autoinflammatory Diseases/drug therapy; Humans; Injections Subcutaneous; Interleukin-1beta/antagonists & inhibitors; Male; Mevalonate Kinase Deficiency/drug therapy; Young AdultAntibodiesInjectionsDose-Response RelationshipYoung Adult03 medical and health sciencesAll institutes and research themes of the Radboud University Medical CenterDouble-Blind MethodGeneral & Internal MedicinemedicineHumansPreschoolAdolescent; Adult; Antibodies Monoclonal; Child; Child Preschool; Dose-Response Relationship Drug; Double-Blind Method; Familial Mediterranean Fever; Female; Fever; Hereditary Autoinflammatory Diseases; Humans; Injections Subcutaneous; Interleukin-1beta; Male; Mevalonate Kinase Deficiency; Young Adult; Medicine (all)030203 arthritis & rheumatologyDose-Response Relationship Drugbusiness.industryHereditary Autoinflammatory DiseasesHyperimmunoglobulinemia Dmedicine.diseaseCanakinumab030104 developmental biologyImmunologyMevalonate Kinase Deficiencybusiness
researchProduct